CRANFORD, N.J., Oct. 25, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on oncology, anti-infective products in adjunct cancer care, unique prescription products, and stem cell therapies, today announced that it will host a key opinion leader (KOL) webinar on the compelling need to salvage central venous catheters in patients with central line associated blood stream infections (CLABSI) on Thursday, November 11, 2021 at 11:30am Eastern Time.
The webinar will feature a presentation by leading infectious disease experts Issam Raad, MD, University of Texas MD Anderson Cancer Center and Mark Rupp, MD, University of Nebraska Medical Center. Dr. Raad will discuss the unmet medical need in the treatment of patients with infected central venous catheters (CVCs), and the potential of Citius's Mino-Lok® treatment to salvage infected catheters. Dr. Rupp will discuss the effect of the COVID-19 Pandemic on CLABSI rates in acute care facilities. Citius Pharmaceuticals' Chief Medical Officer, Myron Czuczman, MD, will provide an update on the company's Mino-Lok® program. Drs. Raad, Rupp and Czuczman will be available to answer questions following the formal presentations.
Pre-registration for the webcast is required.
Date
Thursday, November 11, 2021
Time
11:30 a.m. ET
Registration link
To participate, please register prior to the event date using this link
Webcast (live and archive)
Available at http://www.citiuspharma.com in the "Events" section
Q&A
Questions may be submitted in advance using this link
Featured Speakers
Issam Raad, MD, FACP, FIDSA, FSHEA
Dr. Issam Raad, G. H. Fletcher Distinguished Chair & Professor, Department of Infectious Diseases, Infection Control and Employee Health, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, is considered one of the leading experts in the field of health care related infections and infections in cancer on a worldwide basis. During his more than 25 years at MD Anderson, Dr. Raad has made numerous outstanding clinical research contributions that have led to significant improvements in controlling life-threatening infections for patients with cancer and other serious illnesses throughout the world. His research includes development of innovative antimicrobial central venous catheters and devices that have reduced the risk of bloodstream infections worldwide more than 12-fold. In the most recent CDC Guidelines (2011), his innovations, including the antimicrobial catheters and maximal sterile barrier, have been recommended at the highest level (Category 1A) for the prevention of health care associated bloodstream infections which have become the standard of care.
Mark Rupp, MD
Dr. Mark Rupp, is Chief of the Division of Infectious Diseases and Professor in the Department of Internal Medicine, Section of Infectious Diseases at the University of Nebraska Medical Center. He is the Medical Director of The Nebraska Medical Center Department of Healthcare Epidemiology and Co-Director of the Antimicrobial Stewardship Program. He is a Diplomate, American Board of Internal Medicine, and in the subspecialty area of Infectious Diseases. Dr. Rupp is also a Fellow of the Society for Hospital Epidemiology of America (SHEA), American College of Physicians (ACP), and the Infectious Diseases Society of America (IDSA). He is a Past-President of SHEA and is a past-president of ASM Division L (Infection Control/Hospital Epidemiology). Dr. Rupp has served as a consultant for the US Food and Drug Administration as well as the Centers for Disease Control and Prevention.
Myron Czuczman, MD, Citius Pharmaceuticals Chief Medical Officer
Dr. Czuczman is an experienced physician-scientist, academic oncologist, and pharmaceutical executive with decades of experience in strategic design, implementation, and oversight for the global development of novel therapeutics for hematologic malignancies. Dr. Czuczman joined Citius from Celgene where he was Vice President, Global Clinical Research and Development, Therapeutic Area Head of Lymphoma/CLL. In this role, Dr. Czuczman managed a global team of physicians and scientists responsible for cross-functional development of compounds from proof-of-principle to worldwide registration. Prior to his career in pharma, Dr. Czuczman practiced medicine for over two decades at Roswell Park Cancer Institute, an NCI-designated comprehensive cancer center in Buffalo, NY, where he served as chief of the Lymphoma/Myeloma Service and head of the Lymphoma Translational Research Laboratory. In addition to his extensive publications record, membership and leadership roles on national and international research organizations, and consulting and advisory to dozens of pharma companies, Dr. Czuczman also attained the positions of tenured Professor of Medicine at the State University of New York at Buffalo School of Medicine and Biomedical Sciences and Professor of Oncology at Roswell Park Comprehensive Cancer Center.
Dr. Czuczman received his medical degree from Pennsylvania State University College of Medicine after graduating magna cum laude in biochemistry from the University of Pittsburgh. He completed his Internal Medicine residency training at Weill Cornell North Shore University/MSKCC Program, followed by Medical Oncology/Hematology fellowship training at Memorial Sloan-Kettering Cancer Center in New York City.
About Citius Pharmaceuticals, Inc.
Citius is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapies. The Company has two late-stage product candidates, Mino-Lok®, an antibiotic lock solution for the treatment of patients with catheter-related bloodstream infections (CRBSIs), which is currently enrolling patients in a Phase 3 Pivotal superiority trial, and I/ONTAK (E7777), a novel IL-2R immunotherapy for an initial indication in cutaneous T-cell lymphoma (CTCL), which has completed enrollment in its Pivotal Phase 3 trial. Mino-Lok® was granted Fast Track designation by the U.S. Food and Drug Administration (FDA). I/ONTAK has received orphan drug designation by the FDA for the treatment of CTCL and peripheral T-cell lymphoma (PTCL). Through its subsidiary, NoveCite, Inc., Citius is developing a novel proprietary mesenchymal stem cell treatment derived from induced pluripotent stem cells (iPSCs) for acute respiratory conditions, with a near-term focus on acute respiratory distress syndrome (ARDS) associated with COVID-19. For more information, please visit http://www.citiuspharma.com.
Safe Harbor
This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "plan," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks relating to the results of research and development activities, including those from existing and new pipeline assets; uncertainties relating to preclinical and clinical testing; our need for substantial additional funds; the early stage of products under development; our dependence on third-party suppliers; our ability to successfully undertake and complete clinical trials and the results from those trials for our product candidates; the estimated markets for our product candidates and the acceptance thereof by any market; the ability of our product candidates to impact the quality of life of our target patient populations; our ability to commercialize our products if approved by the FDA; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; our ability to attract, integrate, and retain key personnel; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; our ability to procure cGMP commercial-scale supply; government regulation; competition; as well as other risks described in our SEC filings. These risks have been and may be further impacted by Covid-19. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our Securities and Exchange Commission ("SEC") filings which are available on the SEC's website at http://www.sec.gov, including in our Annual Report on Form 10-K for the year ended September 30, 2020, filed with the SEC on December 16, 2020 and updated by our subsequent filings with the SEC. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.
Investor Relations for Citius Pharmaceuticals:
Ilanit Allen Vice President, Investor Relations and Corporate Communications T: 908-967-6677 x113 E: ir@citiuspharma.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/citius-pharmaceuticals-to-host-key-opinion-leader-webcast-on-the-compelling-need-to-salvage-central-venous-catheters-in-clabsi-patients-301407060.html
SOURCE Citius Pharmaceuticals, Inc.
Read this article:
Citius Pharmaceuticals to Host Key Opinion Leader Webcast on the Compelling Need to Salvage Central Venous Catheters in CLABSI Patients - Stockhouse
- Kyle Orwig received the Distinguished Researcher Award from the American Society for Reproductive Medicine - University of Pittsburgh - October 4th, 2022
- I Have Cancer And I'm Thankful For The Life Science Industry - Clinical Leader - July 19th, 2022
- Whitmer to veto adoption, abortion alternative funds from Michigan budget - Bridge Michigan - July 19th, 2022
- Tevogen Bio Appoints Acclaimed Oncologist and Immunotherapy Expert Neal Flomenberg, M.D. as Chief Scientific Officer and Global Head of R&D - Yahoo... - July 11th, 2022
- Amendment added to PA budget bill would make Pitt, other universities stop fetal tissue research - WPXI Pittsburgh - July 3rd, 2022
- Free Fecal Water Syndrome in Horses and What To Do About It The Horse - TheHorse.com - July 3rd, 2022
- PAWcast: Valedictorian Natalia Orlovsky '22 on Research, Mental Health, and Pandemic Princeton - Princeton Alumni Weekly - July 3rd, 2022
- Opinion | Pro-Life Representatives may be the reason thousands of students cant afford Pitt - The Pitt News - June 22nd, 2022
- Tackling chronic disease with gene and cell therapies - The Irish Times - May 2nd, 2022
- How one inflammatory disorder exacerbates another | Penn Today - Penn Today - May 2nd, 2022
- ChristianaCare and The Wistar Institute Advance Partnership With New Cancer Research Strategies - ChristianaCare News - March 25th, 2022
- The Incredible Story of Emily Whitehead & CAR T-Cell Therapy : Oncology Times - LWW Journals - March 25th, 2022
- Penn State recipients of Whitaker Center's Women of Impact 2021 awards unite through research - The Daily Collegian Online - March 25th, 2022
- NIH, FDA and 15 private organizations join forces to increase effective gene therapies for rare diseases - National Institutes of Health - October 28th, 2021
- FDA, NIH, and 15 private organizations join forces to increase effective gene therapies for rare diseases - FDA.gov - October 28th, 2021
- People and places at Penn | Penn Today - Penn Today - Penn Today - August 18th, 2021
- Millions in federal money flowed to tissue bank that collected fetal 'heart, gonads, legs, brain': report - Fox News - August 5th, 2021
- Bispecific Antibodies Wage a Two-Pronged Attack on Tumors - Curetoday.com - June 23rd, 2021
- Newly Discovered Glycosylated RNA Is All Over Cells: Study - The Scientist - May 25th, 2021
- Penn researchers find a way through the labyrinth keeping CAR-T from solid tumors - Endpoints News - December 7th, 2020
- 'Benjamin Button' discovery could reverse ageing process - Queensland Times - December 7th, 2020
- The story of mRNA: From a loose idea to a tool that may help curb Covid - STAT - November 11th, 2020
- Dr. Andreas Sauerbrey: The right orthopaedic diagnosis is essential to proper care - Sky Hi News - September 12th, 2020
- T cells, B cells and the range of the human bodys immune response A simple decoder - ThePrint - August 10th, 2020
- Are very long-lived trees immortal and what can they teach humans? - ABC News - August 10th, 2020
- Eradicating balding a step closer with new procedure in the cross hairs - The New Daily - June 4th, 2020
- Coming Together to Solve COVID-19 Mysteries | University of Pennsylvania Almanac - UPENN Almanac - June 4th, 2020
- Orthopedics - Pennsylvania Stem Cell Center - May 25th, 2020
- Stem Cell Treatment Bala Cynwyd | Stem Cell Therapy ... - May 25th, 2020
- Vasomune Therapeutics Announces Clinical and Scientific Advisory Board - BioSpace - May 11th, 2020
- Chinas scientists accused of playing God by creating monstrous cloned apes and primates with human organs - The Sun - May 11th, 2020
- Pregnant and positive | Scientists look for COVID-19 immunity in the womb - WHAS11.com - April 23rd, 2020
- Why Choose Us - Pennsylvania Stem Cell Center - April 10th, 2020
- Moderna: A $12 Billion Brand Built On Hope And mRNA - Seeking Alpha - April 10th, 2020
- The potential use of CRISPR to treat disease is gaining momentum - BioNews - January 16th, 2020
- What a time to be alive: Reproductive breakthroughs of the 2010s that changed life as we know it - FOX 10 News Phoenix - January 3rd, 2020
- 2019: The year gene therapy came of age - Jamaica Observer - December 9th, 2019
- Trevena Inc. (TRVN)'s Financial Results Comparing With VistaGen Therapeutics Inc. (NASDAQ:VTGN) - The Broch Herald - December 9th, 2019
- 253 miles in 4 hours: A Syracuse mans race for a lung transplant, and the angel who helped him - syracuse.com - December 1st, 2019
- Head to Head Survey: BioRestorative Therapies (OTCMKTS:BRTX) & Livongo Health (OTCMKTS:LVGO) - Mitchell Messenger - December 1st, 2019
- Critical Review: BioRestorative Therapies (OTCMKTS:BRTX) and Livongo Health (OTCMKTS:LVGO) - NCTY News - November 16th, 2019
- These Israeli Companies Are Finding Innovative Ways To Improve Diabetes Care, Treatment | Health News - NoCamels - Israeli Innovation News - November 16th, 2019
- Reviewing BioRestorative Therapies (OTCMKTS:BRTX) and Livongo Health (OTCMKTS:LVGO) - Mitchell Messenger - November 16th, 2019
- Reviewing Madrigal Pharmaceuticals Inc. (MDGL)'s and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)'s results - MS Wkly - October 30th, 2019
- Gene Therapy/Editing Series 1: A Brief Introduction To Gene Therapy - Seeking Alpha - October 30th, 2019
- AI uncovers genes linked to heart failure - FierceBiotech - September 27th, 2019
- University of Pennsylvania || Cell and Molecular Biology ... - September 7th, 2019
- Robert Lanza - Wikipedia - May 12th, 2019
- Cary Ortho Utilizes Bone Marrow Stem Cells for General ... - May 12th, 2019
- Stem Cell Therapy in Lancaster Pennsylvania | Stem Cell ... - April 24th, 2019
- Lung Institute Review | Do Stem Cell Treatments Work? - April 21st, 2019
- Cells Weekly October 11, 2015 - stemcellassays.com - February 5th, 2019
- Pittsburgh, Pennsylvania - Stem Cells Transplant Institute - November 18th, 2018
- Stem Cell Therapy in York County, Pennsylvania - October 8th, 2018
- Regrowing dental tissue with stem cells from baby teeth ... - October 2nd, 2018
- About Penn's IRM - Institute for Regenerative Medicine - September 16th, 2018
- Stem Cell Treatment - Philadelphia Bala Cynwyd, PA: World ... - August 13th, 2018
- Stem Cell Therapy in Conewago Township, Pennsylvania - July 19th, 2018
- Meetings - October 8th, 2017
- Tucson's Calimmune to be acquired by Australian drug giant - Arizona Daily Star - August 30th, 2017
- Hair Regrowth using Stem Cells | Ashley and Martin - August 30th, 2017
- Bone Marrow Protein May Be Target for Improving Stem Cell Transplants - Penn: Office of University Communications - August 30th, 2017
- Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah(TM) (CTL019), for children and young ... - GlobeNewswire (press release) - August 30th, 2017
- COLUMN: Startling statistics concerning drug deaths in rural communities - Meadville Tribune - August 25th, 2017
- Rare leukemia targeted by modifying patients' immune cells - New Haven Register - August 7th, 2017
- Campus achievement - Sunbury Daily Item - August 7th, 2017
- La Jolla Light News Nuggets: July 27 - La Jolla Light - July 30th, 2017
- 2016 Scientific Program - December 4th, 2016
- Tissue Niches & Resident Stem Cells in Adult Epithelia - GRC - August 26th, 2016
- Knee Stem Cell Therapy and Platelet Procedures Pittsburgh ... - July 2nd, 2015
- Penn vet team points to new colon cancer culprit - March 16th, 2015
- MD Anderson Names Hwu as Head of Cancer Medicine - February 26th, 2015
- Stemiotics Licenses Modified RNA for Cell Reprogramming - December 22nd, 2014
- Penn Medicine Researchers Announce Latest Results of Investigational Cellular Therapy CTL019 - December 8th, 2014
- Cyanide killed hospital employee, official says - November 29th, 2014
- An Eclectic Path to Precision Medicine - November 25th, 2014
- First Study to Convert Adult Human Cells to Hair-Follicle ... - November 2nd, 2014
- Stem Cell and Xenograft Core: Biomedical Research Core ... - October 27th, 2014
- Immune Therapy Induces Remission for Many With a Tough-to-Treat Blood Cancer - October 18th, 2014
- Sangamo BioSciences ZFP Therapeutic Program in HIV/AIDS Featured at Three Major Scientific Conferences in October 2014 - October 16th, 2014